Objective: This retrospective observational study compared 6-month and 1-year real-world glycemic effectiveness among patients initiating GLP-1 receptor agonists (GLP-1RA), dulaglutide (DULA) vs. liraglutide (LIRA) or DULA vs. exenatide QW (EQW), using US claims data (HealthCore Integrated Research Database) between November 2014 and May 2016 (index date=earliest GLP-1RA fill date). Methods: Patients ≥ 18 years old, with T2DM, no claim for GLP-1RA in 6 months pre-index period (baseline), continuous enrollment 6 months pre- and 1-year post-index, ≥ 1 HbA1c result pre-index and 1-year post-index were included. DULA users were propensity-matched 1:1 to LIRA (585 pairs) or EQW (422 pairs) users. Matched cohorts were balanced in baseline patient characteristics: mean age was 53 years, ~50% were males, 59% and 41% initiated on DULA 0.75 mg and 1.5 mg QW, respectively; and 44% and 56% initiated on LIRA 0.6/1.2 mg and 1.8 mg QD, respectively. Results: DULA initiators experienced greater HbA1c reduction compared to LIRA (p < 0.05). HbA1c reduction for DULA initiators was also higher compared to EQW initiators but was not statistically significant. HbA1c change from baseline at 6-month post index was -1.10 and -0.86 for DULA and LIRA respectively (DULA vs. LIRA cohorts); -1.15 and -0.92 for DULA and EQW respectively (DULA vs. EQW cohorts). HbA1c change from baseline at 1-year post index was -0.98 and -0.77 for DULA and LIRA respectively (DULA vs. LIRA cohorts); -1.00 and -0.77 for DULA and EQW respectively (DULA vs. EQW cohorts). Conclusion: HbA1c reduction was greater in GLP-1RA treatment adherent vs nonadherent patients (p < 0.05) . HbA1c change from baseline at 1-year post index was -1.25 and -0.68 (adherent and non-adherent patients respectively) for DULA and -1.06 and -0.57 (adherent and non-adherent patients respectively) for LIRA in DULA vs. LIRA cohorts; -1.32 and -0.60 (adherent and non-adherent patients respectively) for DULA and -1.11 and -0.63 (adherent and non-adherent patients respectively) for EQW in DULA vs. EQW cohorts.